Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function

Alexander I. Salter(Fred Hutch Cancer Center), Richard G. Ivey(Fred Hutch Cancer Center), Jacob J. Kennedy(Fred Hutch Cancer Center), Valentin Voillet(Fred Hutch Cancer Center), Anusha Rajan(Fred Hutch Cancer Center), Eva J. Alderman(Fred Hutch Cancer Center), Uliana J. Voytovich(Fred Hutch Cancer Center), Chenwei Lin(Fred Hutch Cancer Center), Daniel Sommermeyer(Fred Hutch Cancer Center), Lingfeng Liu(Fred Hutch Cancer Center), Jeffrey R. Whiteaker(Fred Hutch Cancer Center), Raphaël Gottardo(Fred Hutch Cancer Center), Amanda G. Paulovich(Fred Hutch Cancer Center), Stanley R. Riddell(University of Washington)
Science Signaling
August 21, 2018
Cited by 494

Abstract

CD28/CD3ζ and 4-1BB/CD3ζ CAR T cells by mass spectrometry and found that both CAR constructs activated similar signaling intermediates. Stimulation of CD28/CD3ζ CARs activated faster and larger-magnitude changes in protein phosphorylation, which correlated with an effector T cell-like phenotype and function. In contrast, 4-1BB/CD3ζ CAR T cells preferentially expressed T cell memory-associated genes and exhibited sustained antitumor activity against established tumors in vivo. Mutagenesis of the CAR CD28 signaling domain demonstrated that the increased CD28/CD3ζ CAR signal intensity was partly related to constitutive association of Lck with this domain in CAR complexes. Our data show that CAR signaling pathways cannot be predicted solely by the domains used to construct the receptor and that signal strength is a key determinant of T cell fate. Thus, tailoring CAR design based on signal strength may lead to improved clinical efficacy and reduced toxicity.


Related Papers

No related papers found

Powered by citation graph analysis